Sentynl Therapeutics Acquires Progerinin to Enhance Rare Disease Portfolio for Progeria Treatment
- Sentynl Therapeutics acquires Progerinin to advance treatment for Hutchinson-Gilford Progeria Syndrome (HGPS).
- The FDA has designated Progerinin as an orphan drug, emphasizing its treatment potential for rare genetic diseases.
- Progerinin is currently in a Phase 2A clinical trial, with results expected before mid-2026.
Sentynl Therapeutics Expands Rare Disease Portfolio with Progerinin Acquisition
Sentynl Therapeutics Inc., a subsidiary of Zydus Lifesciences Limited, announces a significant step in its commitment to addressing rare genetic diseases through its acquisition of Progerinin (SLC-D011). This investigational drug candidate targets Hutchinson-Gilford Progeria Syndrome (HGPS), a rare condition that results in accelerated aging in children due to the accumulation of the progerin protein. The strategic agreement with PRG S&T, a South Korean company specializing in therapies for rare diseases, enables Sentynl to immediately accelerate the clinical development of Progerinin. Notably, the U.S. Food and Drug Administration (FDA) has already designated Progerinin as an orphan drug, highlighting its potential in treating this serious condition.
Under the terms of the agreement, Sentynl will secure full rights to Progerinin upon meeting specific clinical milestones, positioning it as the second treatment focused on HGPS in Sentynl’s portfolio. The company is currently advancing the therapy through a Phase 2A clinical trial, with results expected before mid-2026. This initiative aligns with the overarching mission of Zydus Lifesciences to enhance the quality of life for patients affected by rare conditions. Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences, underscores the acquisition as a pivotal move towards expanding treatment options for HGPS, demonstrating a strong commitment to innovative solutions in the biopharmaceutical field.
Matt Heck, CEO of Sentynl, reinforces this sentiment, stating that the addition of Progerinin signifies an important stride in progeria research, with a focus on translating scientific advancements into effective therapies. Progerinin’s mechanism is intended to counteract the detrimental effects of progerin by restoring nuclear integrity and minimizing cellular damage. While the therapy is still under investigation and not yet approved by regulatory authorities, the foundational research facilitating its development has been supported by The Progeria Research Foundation (PRF). The proactive engagement of Sentynl in pioneering treatments for HGPS showcases the evolving landscape of biopharmaceuticals dedicated to rare diseases.
In summary, Sentynl Therapeutics’ acquisition of Progerinin marks a noteworthy expansion of its portfolio targeting Hutchinson-Gilford Progeria Syndrome. By fostering collaborations with specialized firms like PRG S&T, Sentynl aims to bridge scientific research with practical therapies, reinforcing its dedication to children and families affected by rare genetic disorders. The upcoming clinical trial data sets a critical timeline for evaluating the treatment's efficacy and advancing the understanding of progeria management.